Skip to main content

EnWave Corporation Announces Closing of Fully Subscribed $3 Million LIFE Offering

Not for distribution to United States newswire services or for dissemination in the United States VANCOUVER, British Columbia, Aug. 21, 2025 (GLOBE NEWSWIRE) — EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) is pleased to announce that it has closed its fully subscribed private placement offering (the “Offering”) of common shares of the Company (the “Shares”). The Company raised aggregate gross proceeds of $3,000,000 through the issuance of 7,500,000 Shares at a price of C$0.40 per Share (the “Issue Price”). Clarus Securities Inc. (“Clarus”) acted as lead agent and sole bookrunner for the brokered component of the Offering comprised of 6,125,000 Shares, pursuant to an agency agreement entered into by Clarus and the Company dated as of August 21, 2025. The Company also completed a non-brokered component of...

Continue reading

OceanPal Inc. Announces Reverse Stock Split to Be Effective August 25, 2025

ATHENS, Greece, Aug. 21, 2025 (GLOBE NEWSWIRE) — OceanPal Inc. (NASDAQ: OP) (the “Company”), a global shipping company specializing in the ownership of vessels, announced today that its board of directors has determined to effect a one-for-twenty-five reverse stock split of the Company’s common shares, par value $0.01 per share. The Company’s shareholders approved the reverse stock split at the Company’s annual meeting of shareholders held on May 20, 2025. The reverse stock split will take effect, and the Company’s common shares will begin trading on a split-adjusted basis on NASDAQ, as of the opening of trading on August 25, 2025, under the existing trading symbol “OP”. The CUSIP number of Y6430L301 will be assigned to the Company’s common shares when the reverse stock split becomes effective. When...

Continue reading

Q2 2025: Operating profit better than expected

Announcement no. 11-2025 21 August 2025 North Media Group CEO Lasse Ingemann Brodt on the Group’s performance in Q2 2025:“Our operating profit for Q2 2025 exceeded expectations. The better-than-expected performance was primarily driven by the initial positive effects of the change in business model for the Swedish distribution business SDR, focusing on automated packing of printed matter, and the takeover of local sales from former franchisees. The EBITDA loss in Bekey was also reduced. These positive effects formed the basis of the upgrade of our full-year EBITDA and EBIT guidance announced last week.”         Financial highlights:DKKm Q2 Q2 YTD  2025 2024 2025 2024Revenue 342.3 343.1 652.8 662.0EBITDA 48.4 60.6 59.0 101.5EBIT 32.4 44.1 31.0 56.2EBIT margin (%) 9.5 12.9 4.7 8.5Return on securities 92.7 141.2 -59.0 296.9Cash...

Continue reading

Hovnanian Enterprises Reports Fiscal 2025 Third Quarter Results

Total Revenues Increased 11% Year-Over-YearMet or Exceeded All Guidance Metrics Provided86% of Total Lots Are Optioned, Highest Percentage EverSecond Highest TTM ROE Amongst Midsized Homebuilders MATAWAN, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) — Hovnanian Enterprises, Inc. (NYSE: HOV), a leading national homebuilder, reported results for its fiscal third quarter and nine months ended July 31, 2025. RESULTS FOR THE THREE-MONTH AND NINE-MONTH PERIODS ENDED JULY 31, 2025:Total revenues increased 10.8% to $800.6 million in the third quarter of fiscal 2025, compared with $722.7 million in the same quarter of the prior year. For the nine months ended July 31, 2025, total revenues increased 6.7% to $2.16 billion compared with $2.03 billion in the first nine months of fiscal 2024.Domestic unconsolidated joint ventures(1) sale of homes...

Continue reading

JSC ‘Siguldas ciltslietu un mākslīgās apsēklošanas stacija‘ unaudited interim report for the first six months of 2025

In the first six months of 2025, net turnover was 956.2 thousand euros, which is 24.5% more than in the first six months of the previous year, but profit before corporate income tax was 57.7 thousand euros – 6.0% or 3.7 thousand euros less than in the corresponding period of the previous year. JSC ‘Siguldas ciltslietu un mākslīgās apsēklošanas stacija’ (hereinafter referred to as the Company) is the only producer of high-quality breeding bull semen and one of the largest suppliers of it in Latvia. The second largest field of the Company’s basic economic activities is the milk testing services. The Company also provides other breeding related services – consultations on issues of cattle breeding, feeding and keeping, evaluation of cow exterior, artificial insemination of cows, initial processing of the supervisory data. The company offers...

Continue reading

ZenaTech Signs Agreements to Acquire Two Florida Companies, Expanding Drone as a Service Footprint into Aviation, Defense, and Power Washing

VANCOUVER, British Columbia, Aug. 21, 2025 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a business technology solution provider specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), Enterprise SaaS, and Quantum Computing solutions, announces it has signed offers to acquire two Florida-based companies expected to expand its US DaaS services footprint into drone-based power washing and new aviation, defense, government, and commercial customers. The acquisitions will unlock significant revenue potential as well as diversification across the Southeast region and nationally. One proposed acquisition is a Florida-based power wash services company with operations across multiple counties, marking ZenaTech’s first US entry into the power washing sector. This...

Continue reading

Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™

GAITHERSBURG, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) — As opioid emergencies continue to be the leading cause of accidental death in the United States,1 Emergent BioSolutions (NYSE: EBS) is teaming up with Voices for Awareness and Facing Fentanyl Now in honor of National Fentanyl Prevention and Awareness Day™ on August 21, 2025. As part of this year’s efforts, these leading advocacy organizations and its sponsors will bring their message to Times Square, NYC on the day with several high-visibility billboards that expose fentanyl risks and urge a nationwide call to action to reduce the stigma around opioid poisonings ensuring that more people can be prepared to save a life. Synthetic opioids, such as fentanyl, are a key driver of the opioid epidemic, contributing to nearly 70 percent of all overdose deaths.2 Its undetectable...

Continue reading

Travelers Gain More Parking Control as CMX and OMNIQ Enhance Convenience and Service

Smarter, faster operations: OMNIQ’s AI-powered machine vision automates license plate scanning and matching, helping staff work more efficiently. Seamless traveler convenience: Pay online or via mobile before, during, or after trips. Reducing missed payments. Hands-on customer service: CMX staff assist travelers, set up permits, process in-person payments, and address any system questions. Reliable revenue for essential services: Efficient follow-up on unpaid citations supports funding for critical needs, like snow removal and ongoing airport operations.SALT LAKE CITY, Aug. 21, 2025 (GLOBE NEWSWIRE) —  Houghton County Airport (CMX) is the latest airport to adopt OMNIQ airport management platform, combining advanced AI-powered machine vision with the expertise and dedication of airport staff. Since going live in October 2024,...

Continue reading

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)

SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic congenital adrenal hyperplasia (CAH). Atumelnant is the first and only small molecule ACTH receptor antagonist in clinical development. “Receiving Orphan Drug Designation from the FDA underscores the significant unmet need faced by people living with CAH,” said Dana Pizzuti, M.D., Chief Medical and Development Officer of Crinetics. “Through atumelnant’s innovative mechanism of action, we have developed an ambitious and uncompromising endpoint for our Phase 3 trial, which can demonstrate the ability...

Continue reading

Freight Technologies Announces Second Quarter 2025 Results

Profit margin % improvement | Lower net loss | Fleet Rocket sales HOUSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) — Freight Technologies, Inc. (Nasdaq: FRGT; “Fr8Tech” or the “Company”), a logistics management innovation company, offering a diverse portfolio of technology-driven solutions, released its results for the second quarter ended June 30, 2025, on August 18, 2025. “In the second quarter of 2025, we made further progress on the technological elements of our offerings and continued our transition to a SaaS provider in the logistics space. Fr8Tech completed initial sales of Fleet Rocket, a Transportation Management System (TMS) software solution, released several new features to Fr8App, and improved the operating margins on its brokerage business. Although higher tariffs and trade policy uncertainty impacted the brokerage business...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.